News Focus
News Focus
Followers 35
Posts 8890
Boards Moderated 1
Alias Born 04/04/2020

Re: studythosestocks post# 429775

Monday, 10/21/2024 6:40:40 PM

Monday, October 21, 2024 6:40:40 PM

Post# of 447903
Study, I think some of you guys are confusing the difference between an FDA approved indication and patent infringement. The generic companies have an indication for SHTG. This was granted by FDA. Amarin no longer has patent protection for that indication. Thank you Nevada. We still have patent protection for the CVD indication. FDA isn't the patent Police. The courts are. Generic companies are selling a product considered to be an equivalent to Vascepa. (For the approved indication). The system substitutes that product for any and all indications. This is the basis of the legal controversy. The patent holder can not be held liable for infringement. I don't understand the confusion.
The financial value of Amarin releasing an authorized generic is a different debate.
Sleven,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News